


PHARMACEUTICAL 2023

Eledon Pharmaceuticals Inc. Rank 194 of 446









PHARMACEUTICAL 2023



Eledon Pharmaceuticals Inc. Rank 194 of 446

The relative strengths and weaknesses of Eledon Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Eledon Pharmaceuticals Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 73% points. The greatest weakness of Eledon Pharmaceuticals Inc. is the variable Net Income, reducing the Economic Capital Ratio by 89% points.

The company's Economic Capital Ratio, given in the ranking table, is 112%, being 69% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	59,518
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	6,475
Liabilities, Non-Current	383
Other Assets	33,275
Other Compr. Net Income	0
Other Expenses	48,648
Other Liabilities	1,752
Other Net Income	462
Other Revenues	0
Property and Equipment	0
Research and Development	27,080
Selling, General and Administrative Expense	12,700

Output Variable	Value in 1000 USD
Assets	92,793
Liabilities	8,610
Expenses	88,428
Revenues	0
Stockholders Equity	84,183
Net Income	-87,966
Comprehensive Net Income	-87,966
Economic Capital Ratio	112%

